Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Pretreated Advanced NSCLC With HER2 Exon 20 Mutations
NCT02369484Phase 2Completed
- Sponsor
- ETOP IBCSG Partners Foundation
- Start
- Sep 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by ETOP IBCSG Partners Foundation. Started Sep 2015; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02369484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02369484.